First-line chemotherapy of advanced breast cancer with mitoxantrone, cyclophosphamide and vincristine.
Seventy-five patients with stage 4 breast cancer were treated with a first-line chemotherapy regimen consisting of cyclophosphamide 600 mg/m2, mitoxantrone 12 mg/m2, and vincristine 1.4 mg/m2 (CNV). Objective response was seen in 61/75 (81%) with 17/75 (23%) complete remission (CR). Median duration of response was 38 weeks overall and 51 weeks for patients achieving CR. CNV is an effective regimen for the treatment of advanced breast cancer.
Bezwoda
W R
WR
Department of Medicine, Haematology/Oncology, University of the Witwatersrand, Johannesburg, South Africa.
Dansey
R
R
Seymour
L
L
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D003520:Cyclophosphamide; D008942:Mitoxantrone